Armata Pharmaceuticals Inc ARMP

$3.03 +0.05 (1.68%)

Valuation

Market cap
112,695,000
Revenue TTM
$4,900,000
Net income TTM
$-173,800,000
P/E (trailing)
0.00
P/E (forward)
1.13
Profit margin
-3,546.94%
Debt to equity
-1.27

Trading

Volume
85,800
Avg volume
213,050
Day's range
$2.89 – $3.19
Shares out
37,193,000
Stochastic %K
36%
Beta
1.54
Analysts
Moderate Buy
Price target
$17.50

Price

Company profile

Armata Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company that focuses on the development of targeted bacteriophage therapeutics for antibiotic-resistant infections worldwide. It develops its products using its proprietary bacteriophage-based technology. The company's product candidates include AP-SA02 for the treatment of Staphylococcus aureus bacteremia; and AP-PA03 for Pseudomonas aeruginosa....

Show more

Armata Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company that focuses on the development of targeted bacteriophage therapeutics for antibiotic-resistant infections worldwide. It develops its products using its proprietary bacteriophage-based technology. The company's product candidates include AP-SA02 for the treatment of Staphylococcus aureus bacteremia; and AP-PA03 for Pseudomonas aeruginosa. The company is based in Los Angeles, California. Armata Pharmaceuticals, Inc. is a subsidiary of Innoviva, Inc.

Industry
Biotechnology
Sector
Healthcare
Phone
310 665 2928
Website
https://www.armatapharma.com
Address
5005 McConnell Avenue, Los Angeles, United States

Latest news

No headlines yet.